Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.60 |
| ▸ | MLYCD | O95822 | 11/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28130460 | 0.98 | CES1 (0.58) | CES1MLYCDTRPV1ACHE | |
| Zinc Chloride SCHEMBL28130545 | 0.92 | CES1 (0.52) | CES1MLYCDTRPV1ACHE | |
| SCHEMBL6609486 | 0.87 | CES1 (0.52) | CES1MLYCDTRPV1 | |
| SCHEMBL4167044 | 0.82 | CES1 (0.40) | CES1MLYCD | |
| SCHEMBL27390852 | 0.80 | CES1 (0.36) | CES1 | |
| SCHEMBL27729592 | 0.77 | CES1 (0.35) | CES1MLYCDACHE | |
| SCHEMBL7189485 | 0.76 | PGR (0.41) | CES1MLYCD | |
| SCHEMBL10665081 | 0.76 | ALDH1A1 (0.33) | CES1 | |
| SCHEMBL13008532 | 0.76 | CES1 (0.48) | CES1MLYCDTRPV1ACHE | |
| SCHEMBL33083 | 0.75 | CES1 (1.00) | CES1MLYCDACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | claimed |
| EP-3643703-A1 | EP300/CREBBP INHIBITOR | Daiichi Sankyo Co., Ltd. (JP) | 2020-04-29 | — | — | EP | claimed |
| EP-2928470-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | Siga Technologies, Inc. (US) | 2015-10-14 | — | — | EP | claimed |
| CN-104650851-A | Red phosphorescent iridium complex and preparation method thereof, and organic electroluminescence device | OCEANS KING LIGHTING SCIENCE | 2015-05-27 | — | — | CN | claimed |
| CN-104650150-A | Red phosphorescent iridium complex and preparation method thereof, and organic electroluminescence device | OCEANS KING LIGHTING SCIENCE | 2015-05-27 | — | — | CN | claimed |
| EP-2803658-A1 | Phosphinate ruthenium complexes | IDENIX Pharmaceuticals, Inc. (US) | 2014-11-19 | — | — | EP | claimed |
| US-8765966-B2 | Phosphinate ruthenium complexes | IDENIX PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | claimed |
| WO-2014089378-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2014-06-12 | — | — | WO | claimed |
| US-20130267698-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | IDENIX PHARMACEUTICALS LLC | 2013-10-10 | — | — | US | claimed |
| US-8481748-B2 | Phosphinate ruthenium complexes | IDENIX PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | claimed |
| WO-2004037810-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-06 | — | — | WO | claimed |
| WO-2004037811-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-06 | — | — | WO | claimed |
| US-6177417-B1 | HOST MATERIAL FOR ION SENSORS | Pyun, Hyung Jung (KR) | 2001-01-23 | — | — | US | claimed |
| EP-0830349-B1 | METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS | DU PONT PHARM CO (US) | 2000-03-22 | — | — | EP | claimed |
| US-5877312-A | Method for preparing alkylating agents for their use for alkylating cyclic ureas | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-03-02 | — | — | US | claimed |
| EP-0830349-A1 | METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-03-25 | — | — | EP | claimed |
| US-5637780-A | Method for preparing alkylating agents and their use for alkylating cyclic ureas | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-06-10 | — | — | US | claimed |
| EP-0767770-A1 | METHOD FOR PREPARING ALKYLATING AGENTS AND THEIR USE FOR ALKYLATING CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-04-16 | — | — | EP | claimed |
| WO-1996039393-A1 | METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-12-12 | — | — | WO | claimed |
| WO-1996000708-A1 | METHOD FOR PREPARING ALKYLATING AGENTS AND THEIR USE FOR ALKYLATING CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267698-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | RPIA, NDUFS7, POP1 | CES1 3335/4885MLYCD 589/4885TRPV1 4780/4885 |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | EP300, CREBBP, CREB1 | CES1 1862/4885MLYCD 3871/4885TRPV1 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.